First-in-human Phase I/II clinical trial aims to address a critical unmet medical need in children with Infantile Neuroaxonal Dystrophy (INAD).
FAIRFIELD, N.J. — October 20, 2026 — The INADcure Foundation today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for INAD-101, an investigational gene therapy developed and funded by INADcure for the treatment of Infantile Neuroaxonal Dystrophy (INAD). The clearance allows preparations to move forward for the first-ever gene therapy clinical trial in children affected by INAD, a rare, rapidly progressive, and ultimately fatal neurodegenerative disorder.
The planned Phase I/II clinical trial will evaluate the safety and preliminary efficacy of INAD-101 under the direction of principal investigator Dr. Darius Adams of Atlantic Health in Morristown, New Jersey, with treatment to be administered at Saint Peter’s University Hospital in New Brunswick, New Jersey.
“This is an incredibly emotional moment for our foundation and for the families who have supported this work for so many years,” said Leena Panwala, Founder and Executive Director of INADcure. “We’ve watched children lose their abilities to this devastating disease, and we’ve lost children along the way as we’ve worked toward this clinical trial. Their families have been a constant reminder of why this work matters and why we couldn’t give up. I’m incredibly grateful to everyone who helped us reach this point, proud of what we’ve accomplished together, and hopeful about what lies ahead.”
INAD is caused by pathogenic variants in the PLA2G6 gene, leading to progressive degeneration of the nervous system. Children typically develop symptoms in infancy or early childhood and progressively lose motor and developmental abilities, often experiencing severe muscle stiffness, vision loss, and difficulties with swallowing and breathing. Many affected children do not survive beyond their first decade of life, and there are currently no FDA-approved treatments.
INAD-101 is an investigational adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a functional copy of the PLA2G6 gene to the central nervous system. The therapy aims to restore PLA2G6 protein function and potentially slow or halt disease progression. INAD-101 has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA.
Administered as a single dose into the cerebrospinal fluid through the cisterna magna, INAD-101 will be evaluated in a Phase I/II clinical trial involving children with genetically confirmed INAD. The study will assess safety, tolerability, and preliminary efficacy through neurological and functional assessments, with five years of follow-up after treatment.
“For children with INAD, the disease can progress rapidly, and there are currently no treatments that can stop or slow that progression,” said Dr. Darius Adams, principal investigator at Atlantic Health. “What makes this study particularly important is that INAD-101 is designed to address the disease’s underlying genetic cause rather than its symptoms alone. While we still have much to learn about its safety and potential benefits, this trial will allow us to begin evaluating whether gene therapy could change the course of INAD.”
The advancement of INAD-101 reflects an uncommon approach to therapeutic development, with a nonprofit rare-disease foundation leading and funding the development of an investigational gene therapy toward clinical testing.
After years of seeking pharmaceutical partners, INADcure recognized that the extremely small patient population and limited commercial incentives made traditional industry investment unlikely. Faced with the urgency of a rapidly progressive childhood disease, the foundation made the decision to pursue development through a foundation-led initiative.
Through its Working on a Miracle fundraising campaign, INADcure mobilized families and supporters worldwide to help fund preclinical research, therapy development, and manufacturing. The foundation also assembled a multidisciplinary network of scientists, clinicians, scientific advisors, and development partners whose collective efforts advanced INAD-101 through preclinical studies, manufacturing of clinical trial material, and the regulatory activities necessary for IND submission.
With FDA clearance received and investigational clinical trial material manufactured, INADcure and its clinical partners are completing site preparations, Institutional Review Board (IRB) approvals, and operational activities required before the study can begin.
Additional information regarding trial eligibility, enrollment procedures, and anticipated timelines will be shared as preparations progress. Families can follow updates through INADcure’s official website and the study listing on ClinicalTrials.gov once available.
INAD-101 is an investigational therapy that has not been approved by the FDA or any other regulatory authority; its safety and efficacy have not yet been established.
Infantile Neuroaxonal Dystrophy (INAD) is an ultra-rare, inherited, and fatal neurodegenerative disorder caused by pathogenic variants in the PLA2G6 gene. It is the most severe early-onset form of PLA2G6-associated neurodegeneration (PLAN). The disease typically begins in early childhood and causes progressive neurological deterioration, resulting in the loss of motor, developmental, and other essential functions. There are currently no FDA-approved treatments, and care focuses on managing symptoms and complications.
Founded in 2017, the INADcure Foundation is a 501(c)(3) nonprofit dedicated to advancing treatments, including a cure, for Infantile Neuroaxonal Dystrophy (INAD) and other forms of PLA2G6-related neurodegeneration (PLAN). The foundation funds scientific research, supports affected families, and brings together researchers, clinicians, and development partners to accelerate potential treatments. Through its Working on a Miracle campaign, INADcure has led and funded the development of INAD-101 from preclinical research through IND clearance.
For more information, visit www.INADcure.org and www.WorkingonaMiracle.org.
Media Contact
INADcure Foundation
Leena Panwala, Executive Director
info@INADcure.org
www.INADcure.org